Skip to content

US · COSM · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Cosmos Health Inc. (COSM) intrinsic value and stock valuation

$2.81as of 2026-11-21 · Mkt cap 11.69M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cosmos Health Inc. DCF and intrinsic value

InvestorsCraft values COSM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from COSM’s statements →

Cosmos Health Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Thessaloniki, IL 55438 cosmoshealthinc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$65.3M+3.3% 5y CAGRd
20112025
Net income
-$-19.14M
20112025
Free cash flow
-$-8.5M
20112025
Total equity
$18.4M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$65.3M$54.4M$53.4M$50.4M$56.2M
Operating income-$-16.54M-$-15.54M-$-21.83M-$-7.47M-$-4.53M
Net income-$-19.14M-$-16.18M-$-18.54M-$-13.83M-$-7.96M
EPSd-$-631.89K-$-844.91K-$-1.55M-$-7.17M-$-12.06M
Operating cash flow-$-8.45M-$-7.72M-$-15.64M-$-14.87M-$-7.1M
Capital expenditure-$-60K-$-420K-$-9.17M-$-380K-$-890K
Free cash flow-$-8.5M-$-8.14M-$-24.8M-$-15.25M-$-7.99M
Total assets$65.5M$54.3M$66M$68M$49.4M
Total debt$20M$11.8M$12.4M$12M$27.1M
Net debt$19.3M$11.5M$8.59M-$-8.72M$26.8M
Total equity$18.4M$24.5M$36M$39.7M$4.38M
Cash and short-term investments$760K$340K$3.85M$20.8M$300K
Income statement
20252024202320222021
Revenue$65.3M$54.4M$53.4M$50.4M$56.2M
Cost of revenue$57.4M$50.1M$49M$44.4M$47.9M
Gross profit$7.9M$4.31M$4.35M$5.96M$8.33M
Research and development expenses$520K$530K$0.00$0.00$0.00
Selling, general and administrative expenses$22.6M$12.1M$25.6M$13.2M$12.4M
Other expenses$1.37M$7.23M$610K$190K$450K
Operating expenses$24.4M$19.9M$26.2M$13.4M$12.9M
Cost and expenses$81.8M$70M$75.2M$57.8M$60.8M
Interest income$400K$410K$660K$240K$50K
Interest expense$2.62M$1.01M$870K$3.97M$3.58M
Depreciation and amortization$1.37M$1.25M$610K$190K$450K
Ebitda-$-15.15M-$-13.92M-$-17.06M-$-8.9M-$-3.82M
Operating income-$-16.54M-$-15.54M-$-21.83M-$-7.47M-$-4.53M
Total other income/expenses, net-$-2.6M-$-640K$3.29M-$-5.58M-$-3.31M
Income before tax-$-19.14M-$-16.18M-$-18.54M-$-13.06M-$-7.85M
Income tax expense$0.00$0.00$0.00$780K$110K
Net income-$-19.14M-$-16.18M-$-18.54M-$-13.83M-$-7.96M
Weighted average shares outstanding$30.3M$19.2M$12M$1.93M$660K
Weighted average diluted shares outstanding$30.3M$19.2M$12M$1.93M$660K
Balance sheet
20252024202320222021
Cash and short-term investments$760K$340K$3.85M$20.8M$300K
Net receivables$22.6M$15.9M$21.7M$22.8M$30.1M
Inventory$5.78M$4.36M$4.79M$3.45M$3.15M
Total current assets$38.4M$25.5M$36.6M$56M$39.8M
Property, plant and equipment, net$11.8M$10.4M$11.6M$2.93M$2.93M
Goodwill and intangible assets$7.57M$7.76M$7.68M$710K$490K
Long-term investments$0.00$5.77M$170K$0.00$0.00
Total non-current assets$27.1M$28.9M$29.4M$11.7M$9.6M
Total assets$65.5M$54.3M$66M$68M$49.4M
Accounts payable$14.6M$11.2M$11.9M$10.3M$12.1M
Short-term debt$13.7M$9.76M$8.54M$8.31M$13.6M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$38.3M$25.8M$24.3M$21.8M$29.9M
Long-term debt$6.23M$2.06M$3.89M$3.72M$13.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.78M$4.02M$5.65M$6.63M$15.1M
Capital lease obligations$600K$710K$1.16M$1.12M$1.06M
Total liabilities$47.1M$29.8M$30M$28.4M$45.1M
Common stock$40K$20K$20K$10K$0.00
Retained earnings-$-133.17M-$-114.02M-$-91.64M-$-66.23M-$-34.35M
Accumulated other comprehensive income (loss)$330K-$-2.13M-$-420K-$-1.13M-$-150K
Total equity$18.4M$24.5M$36M$39.7M$4.38M
Total investments$50K$5.8M$190K$10K$10K
Total debt$20M$11.8M$12.4M$12M$27.1M
Net debt$19.3M$11.5M$8.59M-$-8.72M$26.8M
Cash flow statement
20252024202320222021
Net income-$-19.14M-$-16.18M-$-18.54M-$-13.83M-$-7.96M
Depreciation and amortization$1.37M$1.25M$610K$190K$450K
Stock-based compensation$2.31M$1.69M$580K$20K$5.9M
Change in working capital-$-780K$160K-$-7.9M-$-8.69M-$-6.3M
Accounts receivable-$-6.11M$1.23M-$-4.03M-$-7.46M-$-8.46M
Inventory-$-830K$150K-$-890K-$-490K-$-90K
Accounts payable$4.47M$1.05M$720K$1.73M$3.82M
Net cash provided by operating activities-$-8.45M-$-7.72M-$-15.64M-$-14.87M-$-7.1M
Investments in property, plant and equipment-$-60K-$-420K-$-2.98M-$-70K-$-580K
Acquisitions, net$0.00$0.00-$-5.23M$0.00$0.00
Net cash used for investing activities-$-2.01M-$-800K-$-13.76M-$-20K-$-830K
Common stock issued$5.42M$650K$10M$35.3M$250K
Common stock repurchased$0.00$0.00-$-100K$0.00-$-380K
Dividends paid$0.00-$-6.2M$0.00$0.00$0.00
Net cash used for financing activities$14.1M$5.05M$12.7M$35.1M$7.27M
Net change in cash$3.14M-$-3.52M-$-16.92M$20.5M-$-340K
Cash at end of period$3.46M$320K$3.83M$20.8M$290K
Operating cash flow-$-8.45M-$-7.72M-$-15.64M-$-14.87M-$-7.1M
Capital expenditure-$-60K-$-420K-$-9.17M-$-380K-$-890K
Free cash flow-$-8.5M-$-8.14M-$-24.8M-$-15.25M-$-7.99M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cosmos Health Inc.

        Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.

        CEO
        Grigorios Siokas
        Employees
        163
        Beta
        4.15

        Explore

        Frequently asked questions

        What is the intrinsic value of Cosmos Health Inc. (COSM)?

        Cosmos Health Inc. (COSM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is COSM undervalued?

        COSM trades at a price of $2.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.